koko体育app

欢迎来到《koko体育app 学报（医学版）》
牛挺, 刘霆. 血液肿瘤靶向治疗进展[J]. koko体育app 学报（医学版）, 2014, 45(4): 642-646.
引用本文: 牛挺, 刘霆. 鲜血肉瘤靶向疗法疗法最新动态[J]. 上海高中学报（生物学版）, 2014, 45(4): 642-646.
NIU Ting, LIU Ting. Advances in the Target Therapy of Hematological Malignancies[J]. Journal of Sichuan University (Medical Sciences), 2014, 45(4): 642-646.
Citation: NIU Ting, LIU Ting. Advances in the Target Therapy of Hematological Malignancies[J]. Journal of Sichuan University (Medical Sciences), 2014, 45(4): 642-646.

血液肿瘤靶向治疗进展

Advances in the Target Therapy of Hematological Malignancies

  • 摘要: 随着现代生物医学技术如分子生物学、基因组学的快速发展，对血液肿瘤（白血病、淋巴瘤、骨髓瘤）的发病机制有了深入的认识，血液肿瘤的诊断逐渐进入精细化分层诊断，治疗趋势逐渐演化为将新型靶向药物整合到传统的化疗、放疗、造血干细胞移植治疗中。血液肿瘤靶向治疗的重要进展是酪氨酸激酶抑制剂靶向治疗慢性髓细胞白血病，CD20单克隆抗体靶向治疗B细胞淋巴瘤和CD20阳性白血病，FLT3抑制剂靶向治疗FLT3阳性高危急性髓系白血病。本期专题从上述进展反映了血液肿瘤研究的新成果，以及未来血液肿瘤精细化分层诊断和个体化靶向治疗的趋势。  
    Abstract: With the rapid development of modern bio-medical technology, the pathogenesis of hematological malignancies including leukemia, lymphoma, myeloma has been illustrated with more and more attractive details. The diagnosis of hematological malignancies now becomes more precisely and clarified based on the progress than ever before, and the treatments of hematological malignancies keep the evolution in the way of integrating the novel molecular target drugs with conventional chemotherapy, radiotherapy, hematopoietic stem cell transplantation. The pivotal progress in the target therapy of hematological malignancies includes tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia, CD20 monoclonal antibody treatment of B-cell lymphoma and CD20 positive leukemia, FLT3 inhibitors fo the treatment of FLT3 mutation positive high-risk acute myelogenous leukemia. The topics of this issue focus on the advances in this field, which reflects the new achievements in the research of hematological malignancies, and the trends of precise and stratified diagnosis as well as tailored target therapy in the future.  
    • HTML全文
© 2014 《koko体育app 学报（医学版）》编辑部　版权所有 cc

开放获取♎ 本文遵循知识共享署名—非商业性使用4.0国际许可协议（CC BY-NC 4.0），允许第三方对本刊发表的论文自由共享（即在任何媒介以任何形式复制、发行原文）、演绎（即修改、转换或以原文为基础进行创作），必须给出适当的署名，提供指向本文许可协议的链接，同时标明是否对原文作了修改；不得将本文用于商业目的。CC BY-NC 4.0许可协议详情请访问

/

返回文章
返回
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"}); koko体育-koko体育app koko体育-koko体育网页版koko体育app koko体育-全站app下载(官网) m6米乐app|下载 m6米乐app|主頁欢迎您!!